Effectiveness of Implant Therapy Analyzed in a Swedish Population

TLDR

Peri‑implantitis, an inflammatory disease of tissues around dental implants, is increasingly common as the use of implant‑supported therapy rises worldwide. The study examined 588 patients nine years post‑implant placement clinically and radiographically, assessing peri‑implantitis prevalence and identifying risk indicators via multilevel regression analysis. Forty‑five percent of patients exhibited peri‑implantitis, 14.5% had moderate/severe disease, and higher odds were linked to periodontitis, ≥4 implants, specific brands, general practitioner prosthetics, mandibular placement, and crown margins ≤1.5 mm, underscoring its commonality and multifactorial risk profile.

Abstract

Peri-implantitis is an inflammatory disease affecting soft and hard tissues surrounding dental implants. As the global number of individuals that undergo restorative therapy through dental implants increases, peri-implantitis is considered as a major and growing problem in dentistry. A randomly selected sample of 588 patients who all had received implant-supported therapy 9 y earlier was clinically and radiographically examined. Prevalence of peri-implantitis was assessed and risk indicators were identified by multilevel regression analysis. Forty-five percent of all patients presented with peri-implantitis (bleeding on probing/suppuration and bone loss >0.5 mm). Moderate/severe peri-implantitis (bleeding on probing/suppuration and bone loss >2 mm) was diagnosed in 14.5%. Patients with periodontitis and with ≥4 implants, as well as implants of certain brands and prosthetic therapy delivered by general practitioners, exhibited higher odds ratios for moderate/severe peri-implantitis. Similarly, higher odds ratios were identified for implants installed in the mandible and with crown restoration margins positioned ≤1.5 mm from the crestal bone at baseline. It is suggested that peri-implantitis is a common condition and that several patient- and implant-related factors influence the risk for moderate/severe peri-implantitis (ClinicalTrials.gov NCT01825772).